郑州捷安高科股份有限公司 第五届董事会第十七次会议决议公告 证券代码：300845 证券简称：捷安高科 公告编号：2025-031 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 郑州捷安高科股份有限公司（以下简称"公司"）第五届董事会第十七次 会议于 2025 年 6 月 20 日以电话、电子邮件等通讯方式发出通知，并于 2025 年 6 月 24 日以现场结合远程通讯方式召开。 本次会议由公司董事长郑乐观先生主持，应出席董事 9 人，实际参加董事 9 人，其中高志生先生、赵健梅女士、姚加林先生以通讯表决方式出席会议，公 司监事、高级管理人员列席会议。本次会议的召集和召开符合国家有关法律、 法规及《公司章程》的规定，决议合法有效。 二、董事会会议审议情况 本次会议以现场及远程通讯表决的方式，审议通过以下决议： （一）审议通过《关于调整 2022 年限制性股票激励计划及 2022 年第二期 限制性股票激励计划相关事项的议案》 鉴于公司 2024 年年度权益分派已实施完成，根据公司《2022 年限制性股票 激励计划（草案）》及《2022 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

证券代码：300845 证券简称：捷安高科 公告编号：2025-030 郑州捷安高科股份有限公司 关于签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于郑州捷安高科股份有限公司首次公开发行 股票的批复》（证监许可〔2020〕377 号）核准，郑州捷安高科股份有限公司（以 下简称"公司"）公开发行不超 2,309 万股新股，每股面值人民币 1 元，发行价格 为每股人民币 17.63 元，募集资金总额为人民币 407,076,700.00 元，扣除本次 发行费用人民币 66,905,500.00 元，募集资金净额为人民币 340,171,200.00 元。 上述募集资金已经天健会计师事务所（特殊普通合伙）审验，并出具了《郑州捷 安高科股份有限公司验资报告》（天健验〔2020〕6-43 号）。上述募集资金已全部 存放于募集资金专项账户管理，公司与保荐人、存放募集资金的商业银行签署了 《募集资金三方监管协议》。 根据《郑州捷安高科股份有限公司首次公开发行股票并在创业板上市招股说 明书》（ ...

捷安高科（300845）公告，股东南京嘉景企业管理合伙企业(有限合伙)计划减持不超过322万股，占公 司总股本1.5935%。监事杜艳齐先生拟减持不超过189万股，占公司总股本0.9353%。减持方式为集中竞 价或大宗交易，减持期间为公告披露之日起15个交易日后的3个月内。减持原因系个人资金需求及自身 业务需求。 ...

郑州捷安高科股份有限公司 关于监事及持股 5%以上股东减持股份的预披露公告 证券代码：300845 证券简称：捷安高科 公告编号：2025-029 股东、监事杜艳齐先生、持股 5%以上股东南京嘉景企业管理合 伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、持有公司股份 7,611,787 股，占公司总股本 3.7668%的监事杜艳齐先生， 拟计划自本公告之日起 15 个交易日后的 3 个月内以集中竞价方式减持公司股份 不超过 1,890,000 股,占公司总股本比例不超过 0.9353%。 一、计划减持股东的基本情况 1 | 南京嘉景企业管 | | | | | | --- | --- | --- | --- | --- | | 理合伙企业（有限 | 持股 | 5%以上股东 | 11,290,115 | 5.5870% | | 合伙） | | | | | 注：本公告计算相关比例时，总股本剔除公司回购专用账户中的股份数量。 二、本次减持计划的主要内容 1、 减持原因：个人资金 ...

Summary of Key Points Core Viewpoint - The company has increased the implementation subject and established a special account for the raised funds related to the project "AI Vocational Education Platform Construction Project" to enhance the project's execution and comply with regulatory requirements [1][7]. Fundraising Basic Information - The company issued 23.09 million shares at a price of RMB 17.63 per share, raising a total of RMB 407.08 million, with a net amount of RMB 340.17 million after deducting issuance costs [1][2]. Investment Projects - The total investment for the projects is RMB 349.25 million, with RMB 340.17 million allocated from the raised funds [3]. New Implementation Subject - The new implementation subject for the project is Beijing Jiean Shenmou Technology Co., Ltd., which will receive funds through interest-free loans based on project needs [4][5]. New Special Fund Account - A new special fund account will be opened for the project to ensure proper management and usage of the raised funds, strictly adhering to regulatory guidelines [6][7]. Impact on the Company - The addition of the new implementation subject and fund account is aimed at facilitating the project’s execution and does not adversely affect the company's normal operations or the intended use of the raised funds [7][9]. Approval Procedures - The board of directors and the supervisory board have approved the changes, confirming that the adjustments align with the company's operational needs and regulatory compliance [8][9]. Sponsor's Verification Opinion - The sponsor has verified that the changes have been duly approved and comply with relevant regulations, expressing no objections to the new arrangements [10].

Group 1 - The company held its 14th meeting of the 5th Supervisory Board on June 6, 2025, via telephone and email, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to add an implementation entity and establish a special fundraising account for the project "AI Vocational Education Platform Construction Project based on Vocational Education Vertical Large Model," which aligns with the company's operational needs and does not harm shareholder interests [1][2] - The voting results showed unanimous support with 3 votes in favor, 0 against, and 0 abstentions [2]

郑州捷安高科股份有限公司 关于募投项目增加实施主体及募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 郑州捷安高科股份有限公司（以下简称"公司"）于 2025 年 6 月 11 日召开 第五届董事会第十六次会议和第五届监事会第十四次会议，审议通过了《关于募 投项目增加实施主体及募集资金专户的议案》，同意增加公司全资下属公司北京 捷安申谋科技有限公司（以下简称"北京申谋"）为募投项目"基于职教垂类大 模型的 AI 职教平台建设项目"实施主体，同意北京申谋开立募集资金专户，用 于存放实施该项目募集资金的存放、管理和使用。本次增加的募集资金投资项目 实施主体为公司全资下属公司，未改变募集资金使用用途，无需经公司股东大会 审议。现将相关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于郑州捷安高科股份有限公司首次公开发行 股票的批复》（证监许可（2020）377 号）核准，公司向社会公众公开发行人民 币普通股 2,309 万股新股，每股面值人民币 1 元，发行价格为每股人民币 17.63 元，募集资金总额为人民币 407,076,7 ...

证券代码：300845 证券简称：捷安高科 公告编号：2025-026 郑州捷安高科股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议以现场及远程通讯表决的方式，审议通过以下决议： （一）审议通过《关于募投项目增加实施主体及募集资金专户的议案》 具体内容详见公司同日在巨潮资讯网(www.cninfo.com.cn)上披露的《关于 募投项目增加实施主体及募集资金专户的公告》。 本议案已经公司第五届董事会战略委员会第四次会议审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、备查文件 第五届董事会第十六次会议决议。 特此公告。 郑州捷安高科股份有限公司（以下简称"公司"）第五届董事会第十六次 会议于 2025 年 6 月 6 日以电话、电子邮件等通讯方式发出通知，并于 2025 年 6 月 11 日以现场结合远程通讯方式召开。 本次会议由公司董事长郑乐观先生主持，应出席董事 9 人，实际参加董事 9 人，其中张安全先生、靳登阁先生、赵健梅女士、姚加林先生以通讯表决方式 ...

证券代码：300845 证券简称：捷安高科 公告编号：2025-027 郑州捷安高科股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 郑州捷安高科股份有限公司（以下简称"公司"）第五届监事会第十四次 会议于 2025 年 6 月 6 日以电话、电子邮件等方式发出通知，并于 2025 年 6 月 11 日在公司会议室以现场及远程通讯方式召开。 本次会议以现场及远程通讯表决的方式，审议通过以下决议： （一） 审议通过《关于募投项目增加实施主体及募集资金专户的议案》 监事会认为：募投项目"基于职教垂类大模型的 AI 职教平台建设项目"增 加实施主体并新设立募集资金专户的事项，符合公司的实际情况及经营管理需 要，有利于募投项目推进实施，不存在变相改变募集资金的用途和损害股东利 益的情形，符合中国证监会、深圳证券交易所关于上市公司募集资金管理的有 关规定，符合公司及全体股东利益，同意募投项目"基于职教垂类大模型的 AI 职教平台建设项目"增加实施主体及新设募集资金专户。 表决结果为：同意 3 票，反对 ...